Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia
- Alfonso Quintas-Cardama,
- Hagop Kantarjian(corresponding author),
- Susan O'Brien,
- Elias Jabbour,
- Francis Giles,
- Farhad Ravandi
- University of Texas MD Anderson Cancer Center
Scholary Output:
Contribution to journal
Article
Research
Peer-reviewSustainable Development Goals
- SDG 3 Good Health and Well
Abstract
<p>BACKGROUND. Topoisomerase I inhibitors, like topotecan, have activity in myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML). 9-Nitro-camptothecin (9-NC) is a new oral topoisomerase inhibitor with a good safety profile. The aims of the current study were to evaluate the activity and safety of 9-NC in MDS and CMML. METHODS. Adults with a diagnosis of MDS (n = 12) and CMML (n = 32) received 9-NC 2 mg/m<sup>2</sup> orally daily 5 days a week, every 4 to 6 weeks. RESULTS. Overall, 5 (11%) patients achieved complete response (CR), 7 (16%) had a partial response (PR), and 6 (14%) had hematologic improvement (HI), for an overall response rate of 41%. The response rate was similar in MDS and CMML. Severe (Grade 3-4) side effects included nausea and vomiting (7%), diarrhea (18%), other gastrointestinal toxicities (5%), and genitourinary toricities (12%). CONCLUSIONS. 9-NC is active in MDS and CMML. The paucity of available therapies in CMML makes 9-NC a good candidate for further studies as a single agent, or in combination with decitabine, 5-azacitidine or cytarabine.</p>
Publication Information
Output type
Scholary Output:
Contribution to journal
Article
Research
Peer-reviewOriginal language
English (US)Pages from-to (Number of pages)
Pages 1525-1529 (5 pages)Journal (Volume, Issue Number)
Cancer (Volume 107, Issue 7)Publication milestones
- Published - 10/01/2006
Publication status
Published - 10/01/2006
ISSN
0008-543XPublication IDs
- Scopus: 33749633145
- PubMed: 16955510
- ORCID: /0000-0002-8636-1071/work/68888234
Publication metrics
Metrics
SciVal
citations
21
SciVal
FWCI
0.23
SciVal
Author count
11
SciVal
Paper percentile
74
Fractional count
1
Fractional count
0.09
Fractional count
10
Fractional count
0.91
Fractional count
1
Fractional count
1
PlumX, opens in new tab
Citation count
25
Captures
16
